BioSpace News Archive

Leaders from Nationwide Children’s Hospital, Johns Hopkins Medicine, the American Academy of Pediatrics and more are among event speakers

Data position the company to start potential registrational trials with two drugs in two tumor types

Halozyme Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted a Biologics License Application from Genentech, a member of the Roche Group, for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous administration using Halozyme’s ENHANZE® drug delivery technology in combination with intravenous chemotherapy for the treatment of eligible patients with HER2-positive breast cancer..

RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo®

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, announced that it is acquiring the global rights to Movantik® 1, excluding Europe, Canada and Israel, from AstraZeneca.

Arecor Ltd announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners.

HUNT VALLEY, Md. , Feb. 25, 2020 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a pharmaceutical contract development and manufacturing organization (CDMO), announces the expansion of its aseptic filling capacity and capabilities with the addition of a new, fully robotic filling line. Pii has installed a GENiSYS ® R fillin

HELSINKI , Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson’s disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020. H

Feb. 25, 2020 08:05 UTC First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor 79% of evaluable patients achieved disease control on target lesions; 53% experienced tumor regressions 37% achieved durable clinical benefit lasting ≥ 6 months; including four partial regressions so far, overall response rate not yet reached as six patients remain on treatment Treatment well-tolerated with limited side effects observed IMV t

Fixed-dose combination is administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment